Search details
1.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Support Care Cancer
; 30(3): 2455-2465, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34779921
2.
The role of opioids in cancer response to immunotherapy.
J Transl Med
; 19(1): 119, 2021 03 23.
Article
in English
| MEDLINE | ID: mdl-33757546
3.
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference.
Int J Colorectal Dis
; 35(8): 1513-1527, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32382835
4.
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
J Transl Med
; 17(1): 99, 2019 03 27.
Article
in English
| MEDLINE | ID: mdl-30917841
5.
The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy.
Alcohol Alcohol
; 54(1): 47-50, 2019 Jan 01.
Article
in English
| MEDLINE | ID: mdl-30260381
6.
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Eur J Clin Pharmacol
; 73(2): 157-164, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27864592
7.
Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Curr Oncol
; 31(1): 588-597, 2024 01 22.
Article
in English
| MEDLINE | ID: mdl-38275835
8.
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Cancers (Basel)
; 15(18)2023 Sep 15.
Article
in English
| MEDLINE | ID: mdl-37760556
9.
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
J Cancer Res Clin Oncol
; 148(9): 2529-2538, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-34595541
10.
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Clin Cancer Res
; 28(5): 1027-1037, 2022 Mar 01.
Article
in English
| MEDLINE | ID: mdl-34980602
11.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Front Immunol
; 13: 974087, 2022.
Article
in English
| MEDLINE | ID: mdl-36405727
12.
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis.
Front Oncol
; 12: 935826, 2022.
Article
in English
| MEDLINE | ID: mdl-36033477
13.
Merkel Cell Carcinoma.
Biomedicines
; 9(7)2021 Jun 23.
Article
in English
| MEDLINE | ID: mdl-34201709
14.
Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
Biomedicines
; 9(2)2021 Feb 09.
Article
in English
| MEDLINE | ID: mdl-33572373
15.
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study.
Front Oncol
; 11: 712053, 2021.
Article
in English
| MEDLINE | ID: mdl-34778029
16.
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Clin Colorectal Cancer
; 20(4): 318-325, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34380594
17.
Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
Biomedicines
; 8(11)2020 Oct 23.
Article
in English
| MEDLINE | ID: mdl-33113965
18.
[The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.] / Il percorso diagnostico-terapeutico e assistenziale nella gestione del paziente affetto da tumore cutaneo non melanocitario: l'esperienza dell'IDI - IRCCS di Roma.
Recenti Prog Med
; 111(12): 749-760, 2020 12.
Article
in Italian
| MEDLINE | ID: mdl-33362172
19.
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients.
J Pers Med
; 10(4)2020 11 04.
Article
in English
| MEDLINE | ID: mdl-33158018
20.
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Vaccines (Basel)
; 8(2)2020 Apr 28.
Article
in English
| MEDLINE | ID: mdl-32353934